Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESAHOM: Arotinolol Hydrochloride in Essential Hypertension
NCT02612298Phase 4Completed
- Sponsor
- Sumitomo Pharma
- Start
- Aug 2015
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of arotinolol in essential hypertension, sponsored by Sumitomo Pharma. Started Aug 2015; status: completed.
02
Drugs
arotinolol
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT02612298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02612298.